G蛋白偶联受体（GPCR）是人体最大的一类膜蛋白受体家族，不仅调节机体正常生命活动，并与病理、药理过程密切相关，因而成为最主要的药物靶位点。该课题将分析并寻找与非小细胞肺癌（NSCLC）发生与发展中有重要影响的GPCR靶位点。前期研究中利用R软件对GEO数据库NSCLC转录组数据进行生物信息学分析，发现NSCLC中差异基因显著富在Gq蛋白有关的GPCR通路上，进而在通路蛋白互作分析中确定了在GPCR/Gq通路中最为关键两个受体为血管紧张素受体1（AGTR1）和内皮素受体B（EDNRB）。在课题中构建AGTR1和EDNRB过表达稳转细胞系，阐明AGTR1和EDNRB激活或失活对EGF诱导NSCLC促进肿瘤作用及其信号通路网络和代谢组学机制,从而对AGTR1和EDNRB能否成为NSCLC治疗靶点方面提供理论基础。另外，我们研究将对NSCLC治疗与高血压治疗之间产生的“严重冲突”中提出理论方案。

G protein-coupled receptors (GPCR) are the largest family of membrane protein receptors in the human body. They not only regulate the normal life activities, but also are closely related to the pathological and pharmacological processes in the body.So they have become the most important targets for drug development.This study aimed to analyze and look for GPCR targets that have important influence on the development of non-small cell lung cancer (NSCLC). In Preliminary exploration, transcriptome data of NSCLC were bioinformatical analysis using R software from GEO database,as result the genes are significant difference in Gq protein rich in NSCLC GPCR pathways, and in the analysis of protein interactions in the pathways identified in GPCR/Gq pathway is the most crucial two receptors， angiotensin receptor 1 (AGTR1) and endothelin receptor (EDNRB) B.In this study, the overexpressed stable cell lines of AGTR1 and EDNRB were constructed as model experiments to clarify the tumor promoting effects of AGTR1 and EDNRB activation or inactivation on EGF-induced the proliferation and migration of NSCLC, as well as the signal pathway network relationship and the metabolomics mechanism, so as to provide a theoretical basis for whether AGTR1 and EDNRB can be targets for the treatment of non-small cell lung cancer.In addition, our study will propose a theoretical solution to the "serious conflict" between NSCLC treatment and blood pressure adjustment therapy.